Osteoclast is the primary bone resorbing multinucleated cell. However, human osteooclastoma bone tumor derived osteoclat cellsare However, gene expression profile of giant osteoclat cells is unclear. Here, we performed gene expression profiling of enriched giant cells to elucidate the neoplastic effects and dynamic changes in gene expression responsible for abnormal hyperactive osteoclast formation in the tumor bone microenvironment. Overall design: Gene expression profiling was determined in mouse monoclonal (23C6) antibody against integrin alpha V beta 3 receptor purified or enriched human osteoclastoma bone tumors derived giant osteoclast cells